lifestyle.pspl.com

Author: RenovoRx, Inc.

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

May 5, 2026
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting

May 4, 2026
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

May 3, 2026
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

May 3, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

May 2, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

May 2, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

May 2, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

May 1, 2026
RenovoRx Announces $10 Million at Market Private Placement

April 30, 2026
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

February 27, 2026